Mr. Sun is a seasoned life science executive with more than a decade of experience and a strong track record in biotechnology. In addition to Full-Life, he is Partner and Chief Investment Officer at Gordian Ventures, a global life science venture firm focusing on the incubation of companies that possess extremely high technical barriers for entry. Prior to Gordian, he co-founded Silicon Therapeutics and led the company as CEO through its $2.0 billion acquisition by Roivant Sciences (NASDAQ:ROIV) in February 2021.Previously, he served as CEO or Managing Partner at a wide range of healthcare companies and venture capital firms.
Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Europe, the United States, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow.
We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.

-
Leadership Team
-
Lanny SunCo-founder, Chairman & Chief Executive Officer
-
Steffen Heeger, MD, Ph.D.Chief Medical Officer
-
Fa Liu, Ph.D.Chief Scientific Officer
-
Hong-hoi Ting, D.Phil.Co-founder, Board Member & Chief Strategy Officer
-
Philippe van PutGeneral Manager, Europe
-
Nicholas Wong, Ph.D.Co-founder & Chief Operating Officer
-
Julie WuChief Financial Officer
-
James McCarter, Ph.D.Vice President & Head of Radioisotope Technology Research
-
2023. 5Full-Life Technologies completed land purchase in Belgium to establish GMP manufacturing facility for radiopharmaceutical drug production
2023. 5
-
2023. 1Full-Life Technologies Announces Appointment of Chief Medical Officer and Chief Scientific Officer
2023. 1
-
2022.11Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022.11
-
2022. 8Full-Life Technologies Announces Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board
2022. 8
-
2022. 5Full-Life Technologies completed $37 million in series A round financing.
2022. 5
-
2022. 1Full-Life Technologies announced four key appointments to its executive team.
2022. 1
-
2021. 12Full-Life Technologies completed $10 million in seed round financing.
2021. 12
-
2021. 8Full-Life Technologies was Founded.
2021. 8